The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy
The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy
October 30, 2017 By Cade Hildreth (CEO)
What do we know of the safety and efficacy of stem cell therapeutics?
Over 50 years have passed since the discovery of hematopoietic stem cells (bone marrow transplantation to cure diseases such as leukemia), almost 20 years since the discovery of human embryonic stem cells (hESC), and 10 years since the discovery of induced pluripotent stem cells (iPS cells). There are also more than 5,000 stem cell trials ongoing in clinics globally. Despite this experience, what do we actually know about the safety and efficacy of stem cell therapeutics?
In this novel and increasingly complex stem cell space, it is perhaps a timely question to ask, especially since the regulatory assessment criteria designed for conventional medicines are not directly applicable for stem cell therapy.
Safety & efficacy issues with stem cell therapies
Tumorigenicity is a major concern with stem cell therapeutics. Delivery of a cell with unlimited potential for renewal and capacity to differentiate into any human cell type carries a safety concern not associated with any other class of therapy. This is a significant and well accepted issue for hESC and iPS cells as there is growing evidence that their derivatives have similar tumorigenic risk. Even cells derived from autologous iPS cells once considered safe have recently begun to cause concern. A clinical trial using autologous iPS cell derived RPEs (retinal pigment epithelium) was halted in 2015 after only one person had received a treatment. As the lab prepared to treat the second trial participant, two small genetic changes were detected in both the patient’s iPS cells and the RPE cells derived from them.
Immunogenicity is a growing concern and one that remains to be fully elucidated as available scientific evidence is still notoriously contradictory. Although there are reports of immuno-privileged status for some therapeutic stem cells, such as mesenchymal stem cells (MSC) (Drukker and Benvenisty, 2004), any foreign cell introduced into a patient is subject to immune surveillance (Swijnenburget et al., 2008) and will trigger an immune response. Immunogenicity of allogeneic cells is well known, but there is growing evidence that even autologous and syngeneic cell transplants from hESC and iPS cells and their derivatives carry a significant degree of immunogenicity (Gao et al., 2016).
Immunosuppression: attempting to cope with immunogenicity results in significant health risks
Many advocate the use of immunosuppression to get around the immune-rejection of all allogeneic stem cell transplants, but this is starting to become medically questionable. Long-term immunosuppression is not an option due to its inherent adverse side-effects that can even lead to fatality; in addition patients already weakened by the underlying disease/injury or ageing could end up with significant health issues (infections) with a long-term administration of immunosuppressants.
For pluripotent cell derived implants, to suppress the immune system of the recipient at the same time as implanting hESC or iPS cells or their functionally relevant derivatives with a known propensity for tumorigenesis, exposes patients to an unacceptable level of risk since a suppressed immune system is not able to effectively fight off tumors. Finally, safety issues linked to immunogenicity may only allow the patient to be injected safely once in their lifetime with allogeneic cells, as there is evidence that repeated dosing with allogeneic cells could result in a strong immune response against the cells and even anaphylaxis.
Immunogenicity and tumorigenicity are tightly linked through an “unfavorable” balance. This is a fundamental safety issue for allogeneic stem cells. On the other hand with autologous stem cell treatment, the patient’s immune system remains intact and retains its ability to fight off tumors, making autologous stem cell treatment safer.
Inappropriate Differentiation is a concern with stem cells derived from a different lineage than the target tissue or organ where these cells are transplanted. For example, MSC (which differentiate into bone, cartilage, muscle and fat cells) implanted into another tissue or organ such as the heart or brain carry a risk of growing into bone, cartilage and/or fat tissue. In one published case, a woman that was injected with MSCs around her eyes ended up with bone tissue growing inside her eyelids.
Potency or efficacy comes from Cell Replacement (“seed” effect) and Paracrine (“bystander” or “fertilizer” effect) effects of the implanted stem cells. It is important to note that the bystander effect only goes as far as providing growth factors, and cytokines, and other paracrine effects to the host’s existing cells. In cases where significant tissue has been destroyed or is irreparable, paracrine function will have only limited or no effect and only stem cells that can graft and replace cells will provide regrowth of tissue and restore functionality.
Organ Specificity is increasingly important for safe and effective tissue regeneration, which only autologous organ-specific stem cells can ensure. Even organ-specific allogeneic stem cells pose significant safety issues, which need to be weighed against their efficacy limited solely to the bystander effect. While autologous stem cells from a different organ may be safe in many circumstances, their efficacy through paracrine signals including growth factor and cytokines secretion will be limited to the non-specific bystander effects. The paracrine effect is specific to the source tissue / organ (such as bone marrow), instead of the organ that they are implanted into. Therefore, the hopes of a universal donor and an off-the-shelf product (allogeneic non-organ specific) would be exceedingly difficult to implement.
Since harvesting organ-specific stem cells in an autologous manner has its limitations, especially for CNS, direct reprogramming of somatic cells is the optimal method for generating autologous organ-specific stem cells.
*Click to enlarge image.
How do different stem cell therapies stack up against these critical factors?
Increased understanding of hESCs and iPSCs and their progeny are challenging the possibility of translating them into viable stem cell therapeutics. Similarly, MSCs have extended their therapeutic promises beyond their own natural capabilities and these goals are proving to be not only ambitious, but often unrealistic, similar to expecting a liver transplant to work like a kidney transplant on a failed kidney.
hESC and their progeny: immunogenic and tumorigenic
hESC and their progeny have been long known to have risks of tumor/teratoma formation, as well as high immunogenicity. In a key study by Robertson et al., a panel of genetically identical mouse embryonic stem cells that differed from recipient mice only at defined genetic loci resulted in a strong immune response and rejection even with just a single MHC class I gene being different, and the speed of rejection was only slightly slower than with fully allogeneic embryonic stem cells. It would therefore seem like it will be nearly impossible to create universal stem cell banks (even with all the combinations of MHC class antigens) that will not be rejected by the recipient patients (Robertson et al., 2007).
iPS cells and their progeny: tumorigenic and immunogenic, even if autologous
Surprisingly and probably less obvious is the growing evidence that autologous (and syngeneic) iPS cells and their derivatives are immunogenic. “The immunogenicity associated with iPS cells and their progeny seems to be linked to the ectopic expression of certain genes that encode what might best be described as ‘developmental antigens’. Pluripotency is associated with a pattern of gene expression that is normally lost shortly after implantation, precluding any participation of the associated gene products in selection of the T-cell repertoire and the induction of immunological tolerance once thymus organogenesis has occurred later in ontogeny” (Fairchild et al., 2016). For example, Zhao et al. identified nine such genes that fulfilled the criteria of being strongly upregulated upon reprogramming to pluripotency, but failing to be properly silenced upon subsequent differentiation in vitro ( Zhao et al., 2011).
Gao et al. further found that iPS cells and their derivatives lose the memory of their origin and are no longer fully recognized as self by the host’s immune system (Gao et al., 2016). Thus the body no longer recognizes these cells as “autologous”, indicating that it is probably not possible to produce autologous cells via the iPS cell route as was originally hoped.
MSCs: Safer…but what about efficacy?
In contrast to pluripotent cells (ESCs and iPSCs) and their progeny, harvested MSCs, with limited potential for proliferation and differentiation, are considered “safe” as they can hardly form tumors in vivo (Goldring, et al., 2011). Originally viewed as a potential off-the-shelf product for stem cell therapeutics, there is increasing evidence of the inherent immunogenicity of MSCs and thus immune-rejection by the recipient. Major histocompatibility complex (MHC)-class I and II molecules are expressed in MSCs albeit weakly, which makes them potentially less immunogenic than hESC and iPS cells (Gebler, et al., 2012), but they are still immunogenic.
In one published case, Thangakunam et al. found that a repeat injection of the same MSCs resulted in anaphylactic shock in a patient . MSCs are not functionally prepped for all bodily functions, and despite popular beliefs, can only replace tissue of their own lineage: bone, cartilage, and fat. Such tissue replacement and repair require the MSCs to be autologous (the patient’s own cells), and not allogeneic (a donor’s cells); if the cells are allogeneic then they will only provide trophic paracrine support for limited innate regeneration ( “bystander” effect) until the cells are destroyed by the patient’s immune system.
MSCs do not have the ability to replace cells in other organs (e.g. brain, liver or heart) where cells are derived from other lineages, and even the bystander paracrine effect in such organs is limited as it is not specific to those organs. General lack of awareness surrounding this feature has resulted in confusion, whereby for example, MSCs have been implanted into numerous unrelated tissues (e.g. the brain), with expected disappointing limited beneficial effects. (As mentioned above, this approach can also be harmful, as e.g. the in one case where a patient that receiving received a MSCs injected injection into her eye area that started growing bone inside her eye lids).
Direct cell reprogramming for highest safety and efficacy
may represent the first safe and fully functional therapeutic stem cells (Gao et al., 2016). Gao et al. described “induced pluripotency” and its associated developmental gene expression profiles constitute the major difference in immunogenicity and tumorigenicity between “autologous” iPSCs and directly reprogrammed autologous stem cells.
Autologous multipotent stem cells produced by direct reprogramming technology do not have a propensity for tumor formation nor do they stimulate the immune system. Hence, such autologous reprogrammed cells can be injected several times into a patient, allowing for a treatment regimen that could potentially fully regenerate the target tissue or organ. Being autologous, they will not require immunosuppression.
Furthermore, differentiation potential of multipotent stem cells is limited to their own specific lineage: a neural stem cell will only have the ability to form neural tissue through differentiation to astrocyte, oligodendrocyte and neurons. The process of direct reprogramming grants the ability to tailor make stem cells to the right organ and tissue. Being made for the right organ, these multipotent stem cells have the capacity to regenerate through Cell Replacement (“seed” effect) and Paracrine or bystander (“fertilizer” effect) effects.
*Click to enlarge image.
Autologous organ-specific stem cells are the stem cells that were originally intended by many scientists as potentially capable of significant therapeutic effects and even cures. Many placed their hopes on iPS cells and on their potential ability to produce autologous organ-specific stem cells, and 10 years later, iPS cells have found their place as research workhorses, but not into the realm of stem cell therapeutics. With limited MSC-derived products making it through clinical trials, and the ethical and immunogenic issues linked to fetal and embryonic cells, stem cell scientists are now turning toward direct reprogramming as a way of producing autologous organ-specific therapeutic stem cells.
The stem cell industry is at a junction where regulators are attempting to pave the way for safe and efficacious stem cell therapeutics, while ensuring patients with speedy access to treatment. With increasing interest and evidence, directly reprogrammed autologous stem cells are expected to make their way to the clinic as the most promising therapeutic stem cell product.
To learn more, view the “2017 Guide to Regulatory Pathways for Cell Therapies.”